MH unit7(1) Comprehensive Clinical Guide to Substance Use Disorders, Withdrawal Syndromes, and Addiction Pharmacotherapy

Diagnostic Foundations of Addictive Disorders

• Substance Abuse versus Dependence:

  • Substance Abuse is defined clinically as a maladaptive, harmful pattern of chemical use leading to clinically significant impairment or distress.
  • Substance Dependence is characterized as addiction manifested through physiological tolerance, neurochemical withdrawal upon cessation, and recurrent failed attempts to reduce or cease use.

• Non-Substance and Behavioral Addictions:

  • Gambling disorder is recognized as a related non-substance behavioral addiction; it is legally accessible through casinos, electronic gambling machines, and sports betting platforms.
  • Caffeine is technically classified as an addictive substance.
  • Nicotine represents a highly addictive substance disorder.
  • Internet addiction is currently under active clinical investigation; affected individuals exhibit extreme irritability and behavioral distress when internet access is restricted.

• Substance-Induced Disorders:

  • Chemical substances can directly induce secondary psychiatric disorders, including substance-induced anxiety, substance-induced psychosis, and substance-induced mood disorders.

• Multifactorial Etiology of Addiction:

  • Genetic factors: Biological vulnerability is significantly elevated if an individual has a close biological relative with an addictive disorder.
  • Environmental and cultural influences: Peer relationships and family dynamics strongly influence substance use patterns. Continuous exposure to active substance use within social groups fosters adoption of the disorder, necessitating a change in environmental exposure.
  • Inadequate coping mechanisms: Individuals frequently turn to alcohol or substances as an unhealthy, maladaptive coping mechanism to manage psychological distress in the absence of effective coping skills.
  • Neurochemical mechanisms: Psychoactive substances alter endogenous neurotransmitter pathways, particularly by stimulating dopamine release. Dopamine surges produce euphoria, elevated mood, and positive reinforcement (the "high"), driving repeated use.
  • Impaired satiety signaling: Unlike individuals who possess a physiological "stop signal" during substance intake, individuals vulnerable to addiction lack this regulatory feedback, resulting in continuous consumption until profound central nervous system depression and acute intoxication occur.

Alcohol: Pharmacology, Intoxication, and Long-Term Pathology

• Pharmacological Properties:

  • Alcohol is a Central Nervous System (CNS) depressant that undergoes rapid systemic absorption via the gastrointestinal tract.

• Acute Intoxication Profile:

  • Early manifestations include generalized muscular relaxation and a loss of behavioral inhibitions.
  • Progressive signs of intoxication include slurred speech, ataxia (unsteady gait), impaired motor coordination, and deficits in memory and cognitive judgment.
  • Behavioral sequelae encompass emotional lability, interpersonal hostility or physical aggression, and inappropriate sexual conduct.
  • Blackouts occur when an individual remains motorically conscious and capable of physical function, but suffers complete anterograde amnesia with an absence of conscious awareness or memory recall of events.

• Acute Alcohol Overdose and Toxicity:

  • Manifestations of severe overdose include profuse emesis, progressive loss of consciousness, and marked respiratory depression.
  • Critical complications include pulmonary aspiration of vomitus, cardiovascular shock, and death.
  • Emergency medical interventions in acute settings include gastric lavage to evacuate unabsorbed alcohol from the stomach, hemodialysis to accelerate blood clearance, and admission to the intensive care unit (ICU).

• Chronic Pathological Sequelae:

  • Hepatic damage: Development of alcoholic hepatitis and cirrhosis.
  • Gastrointestinal pathology: Pancreatitis.
  • Cardiovascular disease: Alcoholic cardiomyopathy.
  • Neuropsychiatric disorders: Wernicke encephalopathy (referenced as nachyencephalopathy) and alcohol-induced chronic psychosis (Korsakoff psychosis).

Alcohol Withdrawal Syndrome, Detoxification, and Assessment Protocols

• Chronological Trajectory of Withdrawal:

  • Initial withdrawal symptoms typically manifest within $4$ to $12\text{ hours}$ following cessation or significant reduction of alcohol consumption, contingent on baseline intake.
  • Withdrawal symptoms peak on Day $2$ ($48\text{ hours}$ post-cessation).
  • Standard withdrawal duration ranges up to $5\text{ days}$, with severe documented presentations persisting up to $2\text{ weeks}$.

• Clinical Symptomatology:

  • Early to moderate symptoms: Coarse tremors, profuse diaphoresis (sweating), elevated arterial blood pressure, sinus tachycardia, insomnia, psychomotor anxiety, nausea, and emesis.
  • Severe complications: Sensory hallucinations (visual, tactile, auditory), grand mal seizures, and delirium tremens (DTs).
  • Delirium Tremens pathophysiology: The brain experiences severe rebound hyper-excitation following the abrupt removal of alcohol's depressive effect on the CNS, manifesting as altered mental status, visual hallucinations, hyperpyrexia (fever), severe diaphoresis, autonomic storm (extreme hypertension and tachycardia), tremors, and grand mal seizures, which can lead directly to fatal cardiac arrhythmias and death.

• Medical Detoxification Management:

  • Medical detoxification provides a controlled, safe environment to clear alcohol from the body and prevent life-threatening complications.
  • Nursing care requires continuous monitoring of vital signs, level of consciousness (LOC), and the initiation of strict seizure precautions.
  • Mild withdrawal may be managed on an outpatient basis; severe cases require $3$ to $5\text{ days}$ of inpatient medical hospitalization.
  • First-line pharmacotherapy utilizes cross-tolerant benzodiazepines (such as diazepam or lorazepam) to suppress CNS hyperactivity.
  • Nutritional supplementation is mandatory; chronic alcohol use induces a profound thiamine deficiency, necessitating thiamine replacement along with vitamin B12 and folic acid.

• The CIWA Withdrawal Assessment Protocol:

  • Standardized clinical assessment utilizes the CIWA (Clinical Institute Withdrawal Assessment, referenced as CYWA / CWAC / CYAD protocol, documented in Box 19.2 on page 360 of text) to gauge withdrawal severity and determine fixed or symptom-triggered medication dosing:
  • CIWA Score $\le 8$: Mild withdrawal; pharmacologic intervention is not indicated.
  • CIWA Score $8$ to $15$: Moderate withdrawal; pharmacotherapy may be indicated.
  • CIWA Score $> 15$: Severe withdrawal; immediate administration of medication is mandatory.

• Scope of Practice Restrictions for Licensed Practical Nurses (LPNs):

  • LPN scope of practice standards (as reinforced during clinical practice at Pinewood) restrict LPNs from conducting formal patient admissions and independently administering standardized clinical withdrawal protocols such as the CIWA protocol.

Sedatives, Hypnotics, and Anxiolytics

• Drug Classifications:

  • Category encompasses barbiturates, non-barbiturate hypnotics, and benzodiazepines, all functioning as CNS depressants.
  • Primary drugs of abuse within this classification are barbiturates and benzodiazepines.
  • Intended clinical effects include drowsiness, sedation, and anxiolysis (reduction of anxiety).

• Intoxication and Overdose Manifestations:

  • Intoxication signs: Dysarthria (slurred speech), severe motor incoordination, ataxic gait, labile mood, impaired attention and memory, progressing to stupor and coma.
  • Benzodiazepine overdose: Ingestion as a single agent is rarely fatal, producing profound somnolence, lethargy, and mental confusion; treated via gastric lavage, activated charcoal administration, and hemodialysis in severe toxicity.
  • Barbiturate overdose: Highly lethal; causes deep coma, acute respiratory arrest, cardiovascular failure, and death; requires immediate ICU admission, emergency gastric lavage or hemodialysis, and aggressive mechanical ventilatory and cardiovascular hemodynamic support.

• Withdrawal and Detoxification Dynamics:

  • The timing of withdrawal onset correlates inversely with the drug's elimination half-life; agents with a short half-life produce rapid withdrawal onset.
  • Withdrawal symptoms represent physiological rebound opposite to drug actions: Marked elevation in blood pressure, tachycardia, tachypnea, fever, tremors, insomnia, anxiety, nausea, and psychomotor agitation (rapid, restless, purposeless physical movements).
  • Severe withdrawal risks include grand mal seizures and hallucinations.
  • Detoxification protocols require gradual step-down tapering over days to weeks to avert life-threatening complications; abrupt cessation is contraindicated.
  • Tapering protocol model: In an individual maintained on Valium (diazepam) four times daily (QID), both the dosage and frequency are systematically reduced every $3\text{ days}$ until the medication is safely discontinued.

Central Nervous System Stimulants

• Substance Overview:

  • Central Nervous System stimulants induce neurochemical excitation. Key agents include amphetamines, methamphetamines, and cocaine.
  • Legitimate medical use is strictly limited, primarily restricted to pharmacotherapy for Attention-Deficit/Hyperactivity Disorder (ADHD); these agents carry an exceptionally high abuse potential.

• Clinical Intoxication Profile:

  • Psychological effects: Rapid onset of intense euphoria, extreme psychomotor hyperactivity, purposeless fidgeting, hyper-talkative speech, marked anxiety, grandiosity, sensory hallucinations, interpersonal aggression, and severely impaired judgment.
  • Physiological parameters: Acute hypertension, severe sinus tachycardia, pupillary dilation (mydriasis), diaphoresis, chills, nausea, acute chest pain, confusion, and fatal cardiac dysrhythmias.
  • Overdose sequelae: Status epilepticus, coma, and sudden cardiovascular death. Stimulant-related mortality rates are escalating due to widespread polysubstance use.

• Stimulant Withdrawal ("The Crash"):

  • Onset occurs within hours to several days following cessation; the physical syndrome is not inherently life-threatening.
  • Symptom presentation: Profound dysphoria, extreme clinical depression, physical exhaustion, vivid and disturbing nightmares, sleep architecture disturbances (insomnia or hypersomnia), hyperphagia (increased appetite), and either psychomotor agitation or psychomotor retardation (referenced as eupharticium).
  • Critical clinical warning: The severe depressive state following stimulant cessation induces acute suicidal ideation, requiring continuous psychiatric safety monitoring.
  • Pharmacotherapy: There are no approved pharmacological treatments for stimulant withdrawal; clinical management is entirely supportive.

Cannabis: Pharmacodynamics, Effects, and Legal Realities

• Plant Forms and Compounds:

  • Cannabis derivatives encompass marijuana (derived from dried leaves and flowering tops) and hashish (concentrated resinous extract).

• Legal and Jurisdictional Framework:

  • Legal status varies significantly at the state level (e.g., states such as Colorado have legalized adult use, whereas states like Tennessee maintain prohibition).
  • Federal law continues to classify cannabis as an illicit substance, creating conflict between federal and state statutes.
  • State legalization shields individuals from state-level prosecution within that state's borders, but interstate transport into prohibition states or federal drug distribution triggers immediate criminal prosecution.

• Clinical Intoxication Profile:

  • Onset and duration: Rapid absorption following inhalation, peaking within $20$ to $30\text{ minutes}$, with an active duration lasting $2$ to $3\text{ hours}$.
  • Influence of strain: Different chemical strains produce variable responses, ranging from cerebral stimulation ("head high") to deep somatic relaxation ("body high").
  • Subjective effects: Euphoria, heightened relaxation, increased appetite ("the munchies"), lowered behavioral inhibitions, motor incoordination, inappropriate laughter, impaired cognitive judgment, memory deficits, and subjective time distortion.
  • Physiological signs: Conjunctival injection ("bloodshot eyes"), xerostomia (dry mouth, termed "cottonmouth"), mild hypotension, and sinus tachycardia.
  • High-dose toxicity: Acute physical overdose does not occur; however, excessive consumption can precipitate cannabis-induced delirium or acute cannabis-induced psychosis.

• Withdrawal Profile:

  • Cannabis cessation does not produce a clinically debilitating or life-threatening withdrawal syndrome; mild possible symptoms include muscular aches, transient diaphoresis, anxiety, and mild tremors.

Opioids: Intoxication, Acute Overdose Reversal, and Clinical Management

• Substance Scope:

  • Prescription analgesics: Morphine, codeine, oxycodone, methadone, and hydrocodone.
  • Illicit opioids: Heroin and illicit synthetic fentanyl.

• Clinical Intoxication:

  • Manifestations include apathy, psychomotor lethargy, impaired cognitive judgment, psychomotor retardation, marked pupillary constriction (pinpoint pupils / miosis), severe drowsiness, slurred speech, and impaired attention and memory.

• Acute Overdose Triad and Naloxone Intervention:

  • Overdose features: Coma, profound respiratory depression, complete unconsciousness, and death.
  • Emergency reversal: Administration of naloxone (Narcan), an opioid antagonist; repeated dosing is frequently mandatory, particularly when treating overdoses involving potent synthetic opioids.
  • Clinical case illustration: During a nursing school rotation at the Rutherford County adult detention facility (the large facility located on Route 940 / New Salem Highway in Murfreesboro), a female inmate obtained contraband opioids from a newly booked inmate and experienced an acute, unconscious overdose. Following emergency response by the Fire Department and EMS, Narcan was administered. Upon immediate restoration of consciousness, the patient reacted with extreme hostility, shouting, "Why did y'all do that?" as the opioid blockade instantly induced acute withdrawal.

• Opioid Withdrawal Syndrome:

  • Precipitated by abrupt chemical cessation or the administration of an opioid antagonist.
  • Early phase: Subjective anxiety, restlessness, intense chemical cravings, severe lower back pain, and lower extremity pain.
  • Advanced phase: Nausea, emesis, profound dysphoria, lacrimation (excessive tearing), rhinorrhea (rhinitic nasal discharge), diaphoresis, profuse diarrhea, frequent yawning, fever, and insomnia.
  • Clinical course: Symptoms cause extreme distress but are not inherently life-threatening; protracted symptoms such as cravings and anxiety can persist for weeks to months.
  • Pharmacological withdrawal treatment: Methadone substitution protocol, systematically tapered over a $2\text{-week}$ interval to attenuate withdrawal severity.

Hallucinogens and Inhalants

• Hallucinogens:

  • Compounds include Lysergic Acid Diethylamide (LSD), 3,4-Methylenedioxymethamphetamine (MDMA / Ecstasy), and Phencyclidine (PCP).
  • Mechanism and presentation: Profound distortion of reality perception mimicking acute psychosis, characterized by vivid visual hallucinations, depersonalization, extreme anxiety, persecutory paranoia, terror of losing emotional control, and dangerous behavioral disinhibition.
  • Autonomic arousal: Sinus tachycardia, hypertension, hyperpyrexia (elevated temperature), pupillary dilation (mydriasis), hyperreflexia, cardiac palpitations, blurred vision, ataxia, and tremors.
  • Phencyclidine (PCP) toxicity: PCP ingestion precipitates extreme belligerence, physical violence, impulsivity, and unpredictable conduct. True toxic overdose occurs with PCP, producing status epilepticus, severe hypertension, malignant hyperthermia, and respiratory depression. Management requires low-stimulus isolation, cooling devices, pharmacological sedation, and mechanical ventilation.
  • Withdrawal and long-term sequelae: Hallucinogens do not produce a recognized physiological withdrawal syndrome; however, persistent drug cravings and spontaneous sensory flashbacks can recur unpredictably for months up to $5\text{ years}$ post-use.

• Inhalants:

  • Chemical substances: Volatile anesthetics, aliphatic nitrates, and organic solvents (gasoline, adhesive glue, paint thinner, aerosol spray paint), as well as nitrous oxide containers ("whippets" derived from pressurized whipped cream canisters).
  • Chronic organic risks: Irreversible brain damage (encephalopathy), peripheral neuropathy, and chronic hepatic disease.
  • Acute intoxication: Dizziness, dysarthria (slurred speech), ataxia, generalized muscular weakness, diplopia (blurred vision), belligerence, aggression, impaired judgment, progressing to stupor and coma.
  • Acute toxicity and mortality: Inhalants trigger acute respiratory depression, vagal stimulation, fatal cardiac dysrhythmias, bronchospasm, cardiac arrest, suffocation, and aspiration, causing sudden death.
  • Medical management: Emergency critical care support (mechanical ventilation and cardiovascular hemodynamic support) until the substance is cleared. There is no pharmacological antidote to reverse inhalant toxicity; organic neurological trauma is permanent.
  • Withdrawal and chronic sequelae: Lacks an identified physiological withdrawal syndrome or medical detox protocol; chronic users exhibit persistent cravings and frequently develop irreversible dementia, inhalant-induced psychosis, chronic anxiety, or mood disorders.

Treatment Paradigms, Recovery Models, and Relapse Prevention Pharmacotherapy

• Community and Peer Support Recovery Programs:

  • Alcoholics Anonymous (AA): Established in the 1930s; pioneered the 12-Step recovery model emphasizing total chemical abstinence and peer-led support rather than leadership by healthcare professionals.
  • Core recovery philosophies: Guided by key slogans including "One day at a time," "Easy does it," and "Let go and let God."
  • Structure: Individual recovery is guided by seasoned peers (sponsors); meetings are structured as open (accessible to non-alcoholics) or closed (restricted exclusively to recovering individuals), utilizing educational, thematic, and sharing formats.
  • Analogous programs: The 12-Step model is adapted for Narcotics Anonymous (NA), Gamblers Anonymous, and Overeaters Anonymous.
  • Relapse realities: Attaining sobriety does not eliminate the ongoing risk of chemical relapse. Patients with repeated relapses are typically referred to structured extended-care facilities, such as halfway houses.

• Medical Detoxification Settings:

  • Safe medical detoxification requires management within an Emergency Department, an acute inpatient hospital medical unit, or a specialized outpatient clinical setting.

• Relapse Prevention Pharmacotherapy for Alcohol Use Disorder:

  • Disulfiram (Antabuse): Induces a violent physiological illness if ethanol is consumed by inhibiting aldehyde dehydrogenase. Ingestion of alcohol while taking Disulfiram precipitates acute facial flushing, throbbing headache, profuse diaphoresis, nausea, intractable vomiting, severe hypotension, confusion, coma, and potential death.
  • Mandatory Disulfiram patient education: Clients must avoid all exogenous sources of alcohol, including culinary ingredients (cooking wine in sauces, desserts containing vanilla extract, alcohol-infused energy drinks), medicinal preparations (liquid cough syrups), and topical personal care items (mouthwash, perfumes, aftershaves, and skin lotions).
  • Acamprosate (Campral / Camperol): Stabilizes neurochemical signaling to reduce alcohol cravings and abstinence-associated physical discomfort; strictly contraindicated in patients presenting with renal impairment.
  • Naltrexone (ReVia / Vivitrol): Pure opioid receptor antagonist that blunts the reinforcing reward pathways of alcohol, thereby reducing alcohol cravings; accessible as a daily oral tablet or a monthly extended-release intramuscular injection (Vivitrol).

• Pharmacotherapy for Opioid Use Disorder:

  • Methadone: Synthetic full opioid agonist administered as a daily oral maintenance dose; provides a regulated, safe medical alternative to illicit heroin.
  • Levomethadyl: Long-acting synthetic opioid analgesic functioning similarly to methadone.
  • Buprenorphine / Naloxone (Suboxone): Sublingual partial opioid agonist combined with an antagonist; suppresses cravings and prevents withdrawal while mitigating intravenous abuse; requires rigorous clinical surveillance.
  • Ambulatory addiction clinic protocols: In primary care addiction practices managing Suboxone, patients must attend monthly provider visits, submit to strict observed urine drug screening, and maintain documentation of all concurrent prescriptions. Non-compliance (such as refusing drug screens or adulterating specimens) results in immediate cessation of prescription refills. Providers retain full discretion to discharge non-compliant patients, particularly following relapses triggered by emotional crises (e.g., anniversary grief surrounding the death of a child).
  • Naltrexone: Blocks opioid receptors, preventing exogenous opioid effects and diminishing subjective cravings.
  • Clonidine (Catapres): Centrally acting alpha-2 adrenergic agonist utilized off-label to suppress autonomic hyperactivity symptoms (sweating, tachycardia, anxiety) during opioid withdrawal.

• Off-Label Pharmacotherapy for Cocaine Cravings:

  • Off-label pharmacological agents utilized to diminish cocaine cravings include Disulfiram, modafinil (referenced as Adenophil), propranolol (beta-blocker), and topiramate (referenced as copramate).

Questions and Classroom Discussion

• Query: "Does anybody know anybody with a gambling addiction?"

  • Classroom Response: "Yeah."
  • Follow-up Discussion: Confirmation that gambling addiction is highly prevalent and legally permitted in commercial casinos.

• Query: "Gambling is legal?"

  • Classroom Response: "Technically. Like sports betting and stuff like that. That's gambling."
  • Follow-up Discussion: Confirmation that sports betting constitutes gambling; even in regions lacking physical casinos, gambling is legally accessible, and gambling disorder is classified alongside addictions as a non-substance addiction.

• Query: "Who's addicted to caffeine?"

  • Classroom Response: "I'm not ashamed of that."
  • Follow-up Discussion: Confirmation that caffeine dependence is technically classified as an addiction.

• Query: "Do you think if somebody has an addiction disorder that's a friend and you always hang around them, what are you gonna do?"

  • Classroom Response: "Get the addiction. You might assume you're victim."
  • Follow-up Discussion: Reinforcement that peer environments strongly influence behavior ("birds of a feather flock together"), making environmental modification essential for recovery.

• Query: "Alcohol as coping mechanism? Okay, is it a healthy coping mechanism?"

  • Classroom Response: "No."

• Query: "Does some of those changes make people feel good?"

  • Classroom Response: "Mhmm. Yes."
  • Follow-up Discussion: Confirmation that chemical-induced surges in dopamine make individuals feel happy or high, which reinforces the desire to reuse the substance.

• Query: "So what are they gonna keep doing? [referring to individuals lacking a natural stop signal]"

  • Classroom Response: "Drinking and drinking and drinking."
  • Follow-up Discussion: Confirmation that individuals without natural satiety mechanisms continue consuming alcohol until central nervous system depression results in severe intoxication.

• Query: "Well, what is alcohol? A CNS depressant stimulant?"

  • Classroom Response: "Depressant. Depressant."

• Query: "What's blackout?"

  • Classroom Response: "You don't remember nothing. There's no conscious awareness."
  • Follow-up Discussion: Clarification that individuals in a blackout lack conscious awareness and retain no memory of events later, yet remain physically capable of motor function.

• Query: "What happens if they overdose on alcohol? They're gonna start to vomit, they may become unconscious, they may experience respiratory depression. What does that put them at risk for?"

  • Classroom Response: "Aspiration."
  • Follow-up Discussion: Confirmation that pulmonary aspiration is the primary hazard, carrying the risk of cardiovascular shock and death.

• Query: "Long term effects of chronic use of alcohol. Talk to me about it. What can it cause?"

  • Classroom Response: "Liver problems."
  • Follow-up Discussion: Elaboration of hepatic complications (cirrhosis, hepatitis) as well as pancreatitis, cardiomyopathy, Wernicke encephalopathy, and Korsakoff psychosis.

• Query: "What about their blood pressure and heart rate? What do you think it is? [during alcohol withdrawal]"

  • Classroom Response: "Elevated. Elevated. Both of them."

• Query: "Again, is detox… Is that the safe way to rid our body of a substance?"

  • Classroom Response: "Yes. Detoxification is the safe way."

• Query: "What other medication may we… What's the problem with chronic alcohol use? What do we need to replace? Liver? Your electrolytes?"

  • Classroom Response: "Thiamine. They have a thiamine deficiency."
  • Follow-up Discussion: Confirmation of thiamine deficiency in chronic alcohol use and the necessity of immediate thiamine replacement to prevent encephalopathy.

• Query: "So where do you think they're gonna be in the hospital? [barbiturate overdose]"

  • Classroom Response: "ICU. ICU."

• Query: "What about blood pressure and heart rate? What about respiratory rate? Temp? [sedative-hypnotic withdrawal]"

  • Classroom Response: "Increased."

• Query: "What's psychomotor agitation?"

  • Classroom Response: "So a lot of rapid movement."
  • Follow-up Discussion: Confirmation that psychomotor agitation involves rapid, restless physical movement, contrasting with psychomotor retardation.

• Query: "So detoxification, what will we want to do? Are we gonna want to abruptly stop whatever they're taking?"

  • Classroom Response: "No. We're gonna want to taper, gradual tapering over days to weeks."

• Query: "Next is stimulants. So what do these do to the [CNS]?"

  • Classroom Response: "Stimulate. Stimulate. In other words, excite it."

• Query: "What about their pupils, the stimulants?"

  • Classroom Response: "Dilated."

• Query: "So what do we need to watch for? [stimulant withdrawal crash]"

  • Classroom Response: "Suicidal. Suicidal ideation."

• Query: "Next is cannabis. What's cannabis?"

  • Classroom Response: "Marijuana. Marijuana."

• Query: "What typically stands at the end of the day, state or federal? [regarding cannabis legalization in Colorado vs. federal law vs. Tennessee]"

  • Classroom Response: "Federal. Federal… State? As long as you're in the state… But if you bring it back here to Tennessee, then what stands? Oh, you're You're on jail."
  • Follow-up Discussion: Clarification that state legalization protects users inside the state's borders against state prosecution, but transporting cannabis into non-legal states or violating federal trafficking statutes triggers arrest and prosecution.

• Query: "What are their eyes? What about their mouth? [cannabis physiological signs]"

  • Classroom Response: "Red. Blood shot. Blood Blood shot." / "Dry. Dry. Cottonmouth."

• Query: "What are their pupils? [opioid intoxication]"

  • Classroom Response: "Constricted. They're constricted."

• Query: "So what's treatment of opioids? Y'all know this one?"

  • Classroom Response: "Narcan."

• Query: "Has anybody seen Narcan be administered?"

  • Classroom Response: "Mm-mm."
  • Follow-up Discussion: Detailed narrative recounting the emergency administration of Narcan to an unconscious female inmate at the Rutherford County jail facility in Murfreesboro on Route 940.

• Query: "Is alcohol in day to day items? So do we need to tell them to read that list very carefully? [referring to Disulfiram therapy]"

  • Classroom Response: "Yes. Yes."
  • Follow-up Discussion: Reinforcement of strict label checking for culinary sauces, extracts, energy drinks mixed with alcohol, cough medicines, and hygiene products.

• Query: "With opioids, y'all are more familiar with this. What can I It's a safer alternative?"

  • Classroom Response: "Methadone. Methadone. Suboxone."

• Query: "Because what can they do? What can they do? [referring to reasons for strictly supervised urine drug testing in addiction clinics]"

  • Classroom Response: "Sneak something in."
  • Follow-up Discussion: Confirmation that patients under addiction management protocols may attempt to sneak in clean urine samples, necessitating strict observation and leading to occasional clinical confrontation.